We're excited to be attending the 19th Clinical Trials Strategic Summit (CTSS) to engage with top experts, uncover revolutionary solutions, and set the course for clinical trials marked by precision and success.
Our CEO and Co-founder Rust Felix will be presenting on Mitigating Compliance Risks Ahead of ICH E6(R3): Why a New Approach to Biospecimen Management is Necessary. Join him on May 21st to learn about the key language from ICH E6(R3) that will impact your biospecimen management practices as a sponsor, determine how you should should be rethinking your risk profile prior to the transition from R2 to R3, and discover a proactive approach for ensuring compliance.
%20on%20Biospecimen%20Management.png)